Bidirectional Modification of a Galbulimima Alkaloid Identifies Selective Opioid Ligands

Area of Science:

• Medicinal Chemistry
• Neuroscience
• Pharmacology

Background:

• GB18 is a newly identified natural alkaloid acting as a mu- and kappa-opioid receptor antagonist.
• Opioid receptor modulation is crucial for pain management, but current therapies face challenges with side effects.

Purpose of the Study:

• To diversify and optimize the opioid antagonist GB18 into novel ligands with improved pharmacological profiles.
• To explore structure-activity relationships for mu- and kappa-opioid receptor interactions.
• To assess the in vivo efficacy and behavioral effects of optimized compounds.

Main Methods:

• Chemical synthesis involving piperidine-to-pyridine replacement and chemoselective cross-coupling reactions.
• In vitro receptor binding and functional assays to determine affinity, efficacy, and selectivity (mu- vs. kappa-opioid receptors).
• In vivo studies in mice, including assessment of brain penetrance and behavioral responses in an open-field assay.

Main Results:

• Replacement of piperidine with pyridine shifted GB18 from antagonism to partial agonism, increasing kappa-opioid receptor selectivity.
• Development of low- to sub-nanomolar KOR-selective full agonists with biased G protein vs. beta-arrestin2 signaling.
• Demonstrated brain penetrance and anxiolytic-like, exploratory behaviors in mice, correlated with increased G protein signaling preference, without sedation.

Conclusions:

• GB18 and its analogs represent tractable scaffolds for developing novel opioid-based therapeutics.
• Optimization allows for fine-tuning of pharmacological properties, potentially leading to safer and more effective pain management strategies.
• Biased agonism at the kappa-opioid receptor may offer a pathway to dissociate desired therapeutic effects from adverse ones.